These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 27911230)

  • 1. Bromodomain inhibitors and cancer therapy: From structures to applications.
    Pérez-Salvia M; Esteller M
    Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Targets and their Inhibitors in Cancer Therapy.
    Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
    Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological function and histone recognition of family IV bromodomain-containing proteins.
    Lloyd JT; Glass KC
    J Cell Physiol; 2018 Mar; 233(3):1877-1886. PubMed ID: 28500727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small Molecules Targeting the Specific Domains of Histone-Mark Readers in Cancer Therapy.
    Zhu H; Wei T; Cai Y; Jin J
    Molecules; 2020 Jan; 25(3):. PubMed ID: 32013155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromodomains: A novel target for the anticancer therapy.
    Gokani S; Bhatt LK
    Eur J Pharmacol; 2021 Nov; 911():174523. PubMed ID: 34563497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The exploitation of FRET probes to track bromodomain/histone interactions in cells for bromodomain inhibitors.
    Sasaki K; Yoshida M
    Drug Discov Today Technol; 2016 Mar; 19():51-56. PubMed ID: 27769358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain biology and drug discovery.
    Zaware N; Zhou MM
    Nat Struct Mol Biol; 2019 Oct; 26(10):870-879. PubMed ID: 31582847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
    Ramadoss M; Mahadevan V
    Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain-containing factors.
    Gold S; Shilatifard A
    Curr Opin Genet Dev; 2024 Jun; 86():102181. PubMed ID: 38564841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
    Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
    Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule inhibitors of bromodomain-acetyl-lysine interactions.
    Brand M; Measures AR; Wilson BG; Cortopassi WA; Alexander R; Höss M; Hewings DS; Rooney TP; Paton RS; Conway SJ
    ACS Chem Biol; 2015 Jan; 10(1):22-39. PubMed ID: 25549280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
    To KKW; Xing E; Larue RC; Li PK
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromodomains and their pharmacological inhibitors.
    Gallenkamp D; Gelato KA; Haendler B; Weinmann H
    ChemMedChem; 2014 Mar; 9(3):438-64. PubMed ID: 24497428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Bromodomain: A New Target in Emerging Epigenetic Medicine.
    Smith SG; Zhou MM
    ACS Chem Biol; 2016 Mar; 11(3):598-608. PubMed ID: 26596782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy.
    Biswas S; Rao CM
    Eur J Pharmacol; 2018 Oct; 837():8-24. PubMed ID: 30125562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting bromodomains: epigenetic readers of lysine acetylation.
    Filippakopoulos P; Knapp S
    Nat Rev Drug Discov; 2014 May; 13(5):337-56. PubMed ID: 24751816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Epigenetics in Cancer.
    Bennett RL; Licht JD
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():187-207. PubMed ID: 28992434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.